NEJM: Over-diagnosis is halved to effectively detect prostate cancer!

Approximately 1.

But at present, the use of prostate-specific antigen (PSA) testing combined with traditional biopsy screening may lead to overdiagnosis, thereby increasing unnecessary biopsies

Recently, researchers from the Karolinska Institutet in Sweden published a study in the New England Journal of Medicine

This is a non-inferiority test for prostate cancer screening, which aims to compare the screening effects of MRI combined with targeted biopsy and traditional biopsy

If there is a suspected tumor in the MRI group, standard and targeted biopsy (test biopsy group) will be performed

The results of the study showed that in the intention-to-treat population analysis, 192 men (21%) in the trial biopsy group were diagnosed with clinically significant cancer, while 106 men (18%) in the standard biopsy group were diagnosed with clinically significant cancer (non-inferior Sex P<0.

Note: The original text has been deleted

references:

[1] Eklund, M.

[2] MRI can cut overdiagnoses in prostate-cancer screening by half.